US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
US6858615B2
(en)
|
2002-02-19 |
2005-02-22 |
Parion Sciences, Inc. |
Phenyl guanidine sodium channel blockers
|
CA2537841A1
(en)
|
2003-09-06 |
2005-03-24 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
CA2545719A1
(en)
*
|
2003-11-14 |
2005-06-02 |
Vertex Pharmaceuticals Incorporated |
Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters
|
US7977322B2
(en)
|
2004-08-20 |
2011-07-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
CN107501099B
(zh)
*
|
2004-06-24 |
2021-03-19 |
沃泰克斯药物股份有限公司 |
Atp-结合弹夹转运蛋白的调控剂
|
WO2007021982A2
(en)
*
|
2005-08-11 |
2007-02-22 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
EP2395002B1
(en)
|
2005-11-08 |
2014-06-18 |
Vertex Pharmaceuticals Inc. |
Pharmaceutical composition containing a heterocyclic modulator of atp-binding cassette transporters.
|
EP2016065B1
(en)
|
2005-12-28 |
2012-09-19 |
Vertex Pharmaceuticals Incorporated |
1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis
|
PL1993360T3
(pl)
|
2005-12-28 |
2017-08-31 |
Vertex Pharmaceuticals Incorporated |
Stałe postacie n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4- dihydro-4-oksochinolino-3-karboksyamidu
|
US7671221B2
(en)
*
|
2005-12-28 |
2010-03-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
US10022352B2
(en)
|
2006-04-07 |
2018-07-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
US7645789B2
(en)
|
2006-04-07 |
2010-01-12 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
RU2451018C2
(ru)
|
2006-04-07 |
2012-05-20 |
Вертекс Фармасьютикалз Инкорпорейтед |
Модуляторы атф-связывающих кассетных транспортеров
|
CN101478964B
(zh)
*
|
2006-05-12 |
2012-02-29 |
沃泰克斯药物股份有限公司 |
N-[2,4-双(1,1-二甲基乙基)-5-羟苯基]-1,4-二氢-4-氧代喹啉-3-羧酰胺的组合物
|
US8563573B2
(en)
|
2007-11-02 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Azaindole derivatives as CFTR modulators
|
AU2008251504B2
(en)
|
2007-05-09 |
2013-07-18 |
Vertex Pharmaceuticals Incorporated |
Modulators of CFTR
|
NZ583420A
(en)
|
2007-08-24 |
2012-06-29 |
Vertex Pharma |
Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
|
US8551534B2
(en)
*
|
2007-10-10 |
2013-10-08 |
Parion Sciences, Inc. |
Inhaled hypertonic saline delivered by a heated nasal cannula
|
EP3012250B1
(en)
|
2007-11-16 |
2017-11-08 |
Vertex Pharmaceuticals Incorporated |
Isoquinoline modulators of atp-binding cassette transporters
|
US8507534B2
(en)
|
2007-12-07 |
2013-08-13 |
Vertex Pharmaceuticals Incorporated |
Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
US20100036130A1
(en)
*
|
2007-12-07 |
2010-02-11 |
Vertex Pharmaceuticals Incorporated |
Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
|
SI2639222T1
(sl)
|
2007-12-07 |
2016-12-30 |
Vertex Pharmaceuticals Incorporated |
Proces za izdelavo cikloalkilkarboksiamido-piridin benzojskih kislin
|
BRPI0820681A2
(pt)
*
|
2007-12-07 |
2019-09-24 |
Vertex Pharma |
formulações de ácido 3-(6-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilperidin-2-il)benzoico
|
NZ620944A
(en)
|
2008-02-28 |
2015-02-27 |
Vertex Pharma |
Heteroaryl derivatives as cftr modulators
|
SI2615085T1
(sl)
|
2008-03-31 |
2015-11-30 |
Vertex Pharmaceuticals Incorporated |
Piridilni derivati kot cftr-modulatorji
|
US20100256184A1
(en)
*
|
2008-08-13 |
2010-10-07 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
AU2009296271A1
(en)
|
2008-09-29 |
2010-04-01 |
Vertex Pharmaceuticals Incorporated |
Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
US8513282B2
(en)
|
2008-10-23 |
2013-08-20 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
KR101955863B1
(ko)
*
|
2009-03-20 |
2019-03-07 |
버텍스 파마슈티칼스 인코포레이티드 |
낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
|
CN102665715A
(zh)
*
|
2009-10-22 |
2012-09-12 |
沃泰克斯药物股份有限公司 |
治疗囊性纤维化和其他慢性疾病的组合物
|
US8802868B2
(en)
|
2010-03-25 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
|
CA2795748C
(en)
|
2010-04-07 |
2020-12-08 |
Vertex Pharmaceuticals Incorporated |
Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
PL3150198T3
(pl)
†
|
2010-04-07 |
2022-01-17 |
Vertex Pharmaceuticals Incorporated |
Kompozycje farmaceutyczne kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-ilo)cyklopropanokarboksamido)-3-metylopirydyn-2-ylo)benzoesowego i ich podawanie
|
AU2011242454A1
(en)
|
2010-04-22 |
2012-11-08 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
NZ603042A
(en)
|
2010-04-22 |
2015-02-27 |
Vertex Pharma |
Pharmaceutical compositions comprising cftr modulators and administrations thereof
|
EP3045452A1
(en)
|
2010-04-22 |
2016-07-20 |
Vertex Pharmaceuticals Inc. |
Process of producing cycloalkylcarboxamido-indole compounds
|
WO2011146901A1
(en)
*
|
2010-05-20 |
2011-11-24 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
US8563593B2
(en)
|
2010-06-08 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
|
HUE047354T2
(hu)
|
2011-05-18 |
2020-04-28 |
Vertex Pharmaceuticals Europe Ltd |
Ivacaftor deuterizált származékai
|
AU2012255711B2
(en)
|
2011-05-18 |
2017-05-04 |
Vertex Pharmaceuticals (Europe) Limited |
Deuterated derivatives of ivacaftor
|
CN103732213A
(zh)
|
2011-06-07 |
2014-04-16 |
帕里昂科学公司 |
治疗方法
|
US8945605B2
(en)
|
2011-06-07 |
2015-02-03 |
Parion Sciences, Inc. |
Aerosol delivery systems, compositions and methods
|
AR086745A1
(es)
|
2011-06-27 |
2014-01-22 |
Parion Sciences Inc |
3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
|
AU2012335714B2
(en)
|
2011-11-08 |
2017-04-13 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
IL265430B2
(en)
|
2012-02-27 |
2024-08-01 |
Vertex Pharma |
Pharmaceutical preparations containing a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and uses thereof
|
US8674108B2
(en)
|
2012-04-20 |
2014-03-18 |
Vertex Pharmaceuticals Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
HUE039734T2
(hu)
|
2012-05-29 |
2019-01-28 |
Parion Sciences Inc |
Nátriumcsatorna-blokkoló aktivitású, dendrimerszerû amino-amid-származékok száraz szem és más nyálkahártya-megbetegedések kezelésére
|
AR092857A1
(es)
|
2012-07-16 |
2015-05-06 |
Vertex Pharma |
Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
|
MY183582A
(en)
|
2012-11-19 |
2021-02-26 |
Vertex Pharmaceuticals Europe Ltd |
Deuterated cftr potentiators
|
BR112015014178A2
(pt)
|
2012-12-17 |
2017-07-11 |
Parion Sciences Inc |
compostos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil)carbamimidoil) pirazina-2- carboxamida
|
MX2015007796A
(es)
|
2012-12-17 |
2015-09-04 |
Parion Sciences Inc |
Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales.
|
CA2896686A1
(en)
|
2012-12-17 |
2014-06-26 |
Parion Sciences, Inc. |
3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
|
JP6545148B2
(ja)
|
2013-03-13 |
2019-07-17 |
フラットリー ディスカバリー ラブ,エルエルシー |
ピリダジノン化合物及び嚢胞性線維症の治療のための方法
|
JP6963896B2
(ja)
|
2013-11-12 |
2021-11-10 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Cftr媒介性疾患の処置のための医薬組成物を調製する方法
|
US9102633B2
(en)
|
2013-12-13 |
2015-08-11 |
Parion Sciences, Inc. |
Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
|
CN103787968B
(zh)
*
|
2014-02-27 |
2016-04-13 |
上海湖发化学技术有限公司 |
化合物的制备方法
|
HRP20230709T1
(hr)
|
2014-04-15 |
2023-10-13 |
Vertex Pharmaceuticals Incorporated |
Farmaceutski pripravci za liječenje bolesti povezanih s regulatorom provodljivosti transmembrane cistične fibroze
|
GB201415381D0
(en)
|
2014-08-29 |
2014-10-15 |
Algipharma As |
Inhalable powder formulations of alginate oligomers
|
UA125245C2
(uk)
|
2014-10-06 |
2022-02-09 |
Вертекс Фармасьютикалз Інкорпорейтед |
Модулятори регулятора трансмембранної провідності при муковісцидозі
|
AU2015330923B2
(en)
*
|
2014-10-07 |
2020-03-12 |
Vertex Pharmaceuticals Incorporated |
Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
|
CA2968130C
(en)
|
2014-11-18 |
2022-08-16 |
Vertex Pharmaceuticals Incorporated |
Process of conducting high throughput testing high performance liquid chromatography
|
GB201504878D0
(en)
|
2015-03-23 |
2015-05-06 |
Algipharma As |
Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion
|
MA42954A
(fr)
|
2015-09-25 |
2018-08-01 |
Vertex Pharmaceuticals Europe Ltd |
Potentialisateurs cftr deutérés
|
GB201517639D0
(en)
|
2015-10-06 |
2015-11-18 |
Algipharma As |
Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract
|
CN106187887B
(zh)
*
|
2016-07-01 |
2018-08-14 |
上海工程技术大学 |
4-羟基喹啉-3-甲酸的制备方法
|
PT3519401T
(pt)
|
2016-09-30 |
2021-12-27 |
Vertex Pharma |
Modulador de regulador de condutância transmembranar de fibrose quística, composições farmacêuticas, métodos de tratamento e processo para fazer o modulador
|
PT3551622T
(pt)
|
2016-12-09 |
2020-11-12 |
Vertex Pharma |
Modulador do regulador da condutância transmembrana da fibrose quística, composições farmacêuticas, métodos de tratamento e processo de fabrico do modulador
|
US11253509B2
(en)
|
2017-06-08 |
2022-02-22 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
WO2019010092A1
(en)
|
2017-07-01 |
2019-01-10 |
Vertex Pharmaceuticals Incorporated |
COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS
|
WO2019018395A1
(en)
|
2017-07-17 |
2019-01-24 |
Vertex Pharmaceuticals Incorporated |
METHODS OF TREATING CYSTIC FIBROSIS
|
WO2019018353A1
(en)
|
2017-07-17 |
2019-01-24 |
Vertex Pharmaceuticals Incorporated |
METHODS OF TREATING CYSTIC FIBROSIS
|
CN111051280B
(zh)
|
2017-08-02 |
2023-12-22 |
弗特克斯药品有限公司 |
制备吡咯烷化合物的方法
|
CA3079277A1
(en)
|
2017-10-18 |
2019-04-25 |
Jiangsu Hengrui Medicine Co., Ltd. |
Preparation method for tyrosine kinase inhibitor and intermediate thereof
|
EP3697774A1
(en)
|
2017-10-19 |
2020-08-26 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms and compositions of cftr modulators
|
CA3082444A1
(en)
|
2017-12-01 |
2019-06-06 |
Vertex Pharmaceuticals Incorporated |
Processes for making modulators of cystic fibrosis transmembrane conductance regulator
|
US20210228489A1
(en)
|
2017-12-04 |
2021-07-29 |
Vertex Pharmaceuticals Incorporated |
Compositions for treating cystic fibrosis
|
JP7245834B2
(ja)
|
2017-12-08 |
2023-03-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを作成するためのプロセス
|
TWI810243B
(zh)
|
2018-02-05 |
2023-08-01 |
美商維泰克斯製藥公司 |
用於治療囊腫纖化症之醫藥組合物
|
MA51828B1
(fr)
|
2018-02-15 |
2022-11-30 |
Vertex Pharma |
Macrocycles utilisés en tant que modulateurs du régulateur de la conductance transmembranaire de fibrose kystique, compositions pharmaceutiques de ceux-ci, leur utilisation dans le traitement de la fibrose kystique et procédé de fabrication associé
|
WO2019195739A1
(en)
|
2018-04-05 |
2019-10-10 |
Alexander Russell Abela |
Modulators of cystic fibrosis transmembrane conductance regulator
|
US11414439B2
(en)
|
2018-04-13 |
2022-08-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
|
EP3880197B1
(en)
|
2018-11-14 |
2023-02-22 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
AR118555A1
(es)
|
2019-04-03 |
2021-10-20 |
Vertex Pharma |
Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
WO2020214921A1
(en)
|
2019-04-17 |
2020-10-22 |
Vertex Pharmaceuticals Incorporated |
Solid forms of modulators of cftr
|
WO2020226889A1
(en)
*
|
2019-05-07 |
2020-11-12 |
Wellstat Therapeutics Corporation |
Formulations of uridine triacetate in triacetin
|
WO2020242935A1
(en)
|
2019-05-29 |
2020-12-03 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
TW202115092A
(zh)
|
2019-08-14 |
2021-04-16 |
美商維泰克斯製藥公司 |
囊腫纖維化跨膜傳導調節蛋白之調節劑
|
US11873300B2
(en)
|
2019-08-14 |
2024-01-16 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms of CFTR modulators
|
WO2021030556A1
(en)
|
2019-08-14 |
2021-02-18 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
TW202120517A
(zh)
|
2019-08-14 |
2021-06-01 |
美商維泰克斯製藥公司 |
製備cftr調節劑之方法
|
WO2022194399A1
(en)
|
2020-07-13 |
2022-09-22 |
Idorsia Pharmaceuticals Ltd |
Macrocycles as cftr modulators
|
CR20230120A
(es)
|
2020-08-07 |
2023-09-01 |
Vertex Pharma |
Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
AU2021325923A1
(en)
|
2020-08-13 |
2023-04-06 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms of CFTR modulators
|
EP4225446A1
(en)
|
2020-10-07 |
2023-08-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
MX2023004073A
(es)
|
2020-10-07 |
2023-07-05 |
Vertex Pharma |
Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica.
|
US20230373935A1
(en)
|
2020-10-07 |
2023-11-23 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
EP4225764A1
(en)
|
2020-10-07 |
2023-08-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
US20230373939A1
(en)
|
2020-10-07 |
2023-11-23 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
WO2022076618A1
(en)
|
2020-10-07 |
2022-04-14 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
WO2022076626A1
(en)
|
2020-10-07 |
2022-04-14 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
AU2021358512A1
(en)
|
2020-10-07 |
2023-05-18 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
WO2022076629A1
(en)
|
2020-10-07 |
2022-04-14 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
EP4304593A4
(en)
*
|
2021-03-09 |
2024-08-07 |
Laurus Labs Ltd |
ORAL FILM OF CFTR MODULATOR(S)
|
TW202333699A
(zh)
|
2022-02-03 |
2023-09-01 |
美商維泰克斯製藥公司 |
囊腫纖維化之治療方法
|
WO2023154291A1
(en)
|
2022-02-08 |
2023-08-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
WO2023196429A1
(en)
|
2022-04-06 |
2023-10-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
WO2023224931A1
(en)
|
2022-05-16 |
2023-11-23 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
EP4335434A1
(en)
|
2022-08-17 |
2024-03-13 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Pharmaceutical compositions comprising ivacaftor
|
WO2024056798A1
(en)
|
2022-09-15 |
2024-03-21 |
Idorsia Pharmaceuticals Ltd |
Macrocyclic cftr modulators
|
TW202421636A
(zh)
|
2022-09-15 |
2024-06-01 |
瑞士商愛杜西亞製藥有限公司 |
(3S,7S,10R,13R)-13-苄基-20-氟-7-異丁基-N-(2-(3-甲氧基-1,2,4-㗁二唑-5-基)乙基)-6,9-二甲基-1,5,8,11-四側氧基-10-(2,2,2-三氟乙基)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-十四氫-[1]㗁[4,7,10,14]四氮雜環十七烷并[16,17-f]喹啉-3-甲醯胺的晶型
|
WO2024056791A1
(en)
|
2022-09-15 |
2024-03-21 |
Idorsia Pharmaceuticals Ltd |
Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators
|